A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

NCT01339897 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: 5 mg/N6022
DRUG: Placebo
DRUG: 10mg/N6022
DRUG: 20mg/N6022

Sponsor

Nivalis Therapeutics, Inc.